Disc Medicine Inc (IRON)

$85.63 +1.94 (2.32%)
Market Cap 2.91B
Revenue (ttm) 0.00
Net Income (ttm) -109.36M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.05
Volume 322,500
Avg Vol 439,650
Day's Range N/A - N/A
Shares Out 34.77M
Stochastic %K 59%
Beta 0.80
Analysts Strong Sell
Price Target $108.82

Company Profile

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeost...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 674 9274
Address:
321 Arsenal Street, Suite 101, Watertown, United States
IN0V8
IN0V8 Oct. 24 at 7:24 PM
$IRON Buy Jefferies raises target price to $127 from $111
0 · Reply
Jamonda
Jamonda Oct. 22 at 5:26 PM
In case anyone missed it. $IRON offering priced at $84.00 1. Company sold 2,619,049 shares + 59,523 pre-funded warrants (ex. price $0.0001) 2. Selling shareholders sold 297,619 shares 3. Underwriters exercised full over-allotment (446,428 shares) on Oct 21, 2025 Net new (dilutive): ~2.679M shares (including warrants when exercised) Secondary: ~744k shares Total to public: ~3.363M shares + 59.5k warrants From: https://ir.discmedicine.com/static-files/57f167cc-4582-44c0-a1c6-520a7edcb2a9
1 · Reply
Strangperson
Strangperson Oct. 22 at 4:04 PM
$IRON my only green stock. Guess I should have bought bynd 😆
0 · Reply
S_Franconi
S_Franconi Oct. 21 at 3:51 PM
$CELC $RVMD $IRON $RYTM
0 · Reply
S_Franconi
S_Franconi Oct. 20 at 1:26 PM
$IRON Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-proposed-public-offering-common-stock-1
0 · Reply
S_Franconi
S_Franconi Oct. 20 at 1:26 PM
$IRON Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-provides-update-hematology-portfolio-and-outlines
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 20 at 12:52 PM
$IRON (-2.7% pre) Disc Medicine announces $220M public stock offering https://ooc.bz/l/81184
0 · Reply
StockBraker
StockBraker Oct. 20 at 11:06 AM
$IRON Disc Medicine announces proposed public offering of common stock and pre-funded warrants
0 · Reply
fallondpicks
fallondpicks Oct. 19 at 9:42 PM
19 #stockbreakouts $IRON (gap), $LBRT (base and 200-day MA), $ACHV (gap). Two sub-$1, five $1-2.
2 · Reply
RunnerSignals
RunnerSignals Oct. 17 at 8:22 PM
Top Movers!​ $ACHV $IRON flying on FDA vouchers $BYND buying time with debt swap while $AGH quietly climbing day 5 https://stocksrunner.com/news/2025-10-17-top-movers-and-shakers-making-waves-in-today-trading-session
0 · Reply
Latest News on IRON
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Oct 21, 2025, 12:14 AM EDT - 4 days ago

Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine: NDA Submission And CNPV For Bitopertin Further Boost Shareholder Value

Oct 20, 2025, 9:15 AM EDT - 5 days ago

Disc Medicine: NDA Submission And CNPV For Bitopertin Further Boost Shareholder Value

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Oct 20, 2025, 7:00 AM EDT - 5 days ago

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

Oct 20, 2025, 6:30 AM EDT - 5 days ago

Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

Oct 17, 2025, 9:00 AM EDT - 8 days ago

Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)

Sep 30, 2025, 8:30 AM EDT - 25 days ago

Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)

Disc Medicine, Inc. (IRON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 10, 2025, 4:39 PM EDT - 6 weeks ago

Disc Medicine, Inc. (IRON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Disc Medicine Appoints Nadim Ahmed to its Board of Directors

Jul 14, 2025, 8:30 AM EDT - 3 months ago

Disc Medicine Appoints Nadim Ahmed to its Board of Directors

Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

Jun 12, 2025, 7:30 AM EDT - 4 months ago

Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

Disc Medicine to Participate in Upcoming Investor Conferences

May 28, 2025, 4:01 PM EDT - 5 months ago

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress

May 14, 2025, 9:30 AM EDT - 5 months ago

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress

Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 8:00 AM EDT - 6 months ago

Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update

Disc Medicine: Forging Ahead In Hematology

Apr 9, 2025, 7:13 AM EDT - 7 months ago

Disc Medicine: Forging Ahead In Hematology

Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 8:00 AM EST - 8 months ago

Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Jan 22, 2025, 9:35 PM EST - 9 months ago

Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Jan 22, 2025, 8:10 AM EST - 9 months ago

Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

PRGS

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 21, 2025, 4:01 PM EST - 9 months ago

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

Jan 21, 2025, 7:45 AM EST - 9 months ago

Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Jan 20, 2025, 7:00 PM EST - 9 months ago

Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)

Jan 17, 2025, 4:00 PM EST - 10 months ago

Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)

Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

Dec 9, 2024, 12:00 PM EST - 11 months ago

Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

Dec 8, 2024, 8:00 PM EST - 11 months ago

Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

Nov 8, 2024, 8:30 AM EST - 1 year ago

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

Nov 4, 2024, 7:50 AM EST - 1 year ago

Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Nov 1, 2024, 4:01 PM EDT - 1 year ago

Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week

Oct 25, 2024, 1:00 PM EDT - 1 year ago

Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week

Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

Sep 19, 2024, 8:30 AM EDT - 1 year ago

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Jun 14, 2024, 1:26 PM EDT - 1 year ago

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Disc Medicine Announces Underwritten Offering of Common Stock

Jun 14, 2024, 8:03 AM EDT - 1 year ago

Disc Medicine Announces Underwritten Offering of Common Stock

Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress

Jun 14, 2024, 7:30 AM EDT - 1 year ago

Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress

Disc Medicine to Participate in the Jefferies Global Healthcare Conference

May 30, 2024, 9:00 AM EDT - 1 year ago

Disc Medicine to Participate in the Jefferies Global Healthcare Conference

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress

May 14, 2024, 10:30 AM EDT - 1 year ago

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress

Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 8:00 AM EDT - 1 year ago

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON)

Apr 2, 2024, 8:01 AM EDT - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON)

HUM

Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)

Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 21, 2024, 8:00 AM EDT - 1 year ago

Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024

Mar 6, 2024, 4:30 PM EST - 1 year ago

Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

Feb 26, 2024, 8:30 AM EST - 1 year ago

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

FDA Grants Orphan Drug Designation to 9MW3011

Feb 20, 2024, 9:00 AM EST - 1 year ago

FDA Grants Orphan Drug Designation to 9MW3011

Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

Feb 20, 2024, 8:30 AM EST - 1 year ago

Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

Feb 9, 2024, 9:00 AM EST - 1 year ago

Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer

Feb 7, 2024, 8:00 AM EST - 1 year ago

Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer

Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 5:00 PM EST - 1 year ago

Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

Dec 20, 2023, 4:30 PM EST - 2 years ago

Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting

Dec 11, 2023, 8:30 PM EST - 2 years ago

Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting

Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting

Dec 11, 2023, 12:00 PM EST - 2 years ago

Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting

Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin

Nov 14, 2023, 4:44 PM EST - 2 years ago

Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin

Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 9, 2023, 8:30 AM EST - 2 years ago

Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update

IN0V8
IN0V8 Oct. 24 at 7:24 PM
$IRON Buy Jefferies raises target price to $127 from $111
0 · Reply
Jamonda
Jamonda Oct. 22 at 5:26 PM
In case anyone missed it. $IRON offering priced at $84.00 1. Company sold 2,619,049 shares + 59,523 pre-funded warrants (ex. price $0.0001) 2. Selling shareholders sold 297,619 shares 3. Underwriters exercised full over-allotment (446,428 shares) on Oct 21, 2025 Net new (dilutive): ~2.679M shares (including warrants when exercised) Secondary: ~744k shares Total to public: ~3.363M shares + 59.5k warrants From: https://ir.discmedicine.com/static-files/57f167cc-4582-44c0-a1c6-520a7edcb2a9
1 · Reply
Strangperson
Strangperson Oct. 22 at 4:04 PM
$IRON my only green stock. Guess I should have bought bynd 😆
0 · Reply
S_Franconi
S_Franconi Oct. 21 at 3:51 PM
$CELC $RVMD $IRON $RYTM
0 · Reply
S_Franconi
S_Franconi Oct. 20 at 1:26 PM
$IRON Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-proposed-public-offering-common-stock-1
0 · Reply
S_Franconi
S_Franconi Oct. 20 at 1:26 PM
$IRON Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-provides-update-hematology-portfolio-and-outlines
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 20 at 12:52 PM
$IRON (-2.7% pre) Disc Medicine announces $220M public stock offering https://ooc.bz/l/81184
0 · Reply
StockBraker
StockBraker Oct. 20 at 11:06 AM
$IRON Disc Medicine announces proposed public offering of common stock and pre-funded warrants
0 · Reply
fallondpicks
fallondpicks Oct. 19 at 9:42 PM
19 #stockbreakouts $IRON (gap), $LBRT (base and 200-day MA), $ACHV (gap). Two sub-$1, five $1-2.
2 · Reply
RunnerSignals
RunnerSignals Oct. 17 at 8:22 PM
Top Movers!​ $ACHV $IRON flying on FDA vouchers $BYND buying time with debt swap while $AGH quietly climbing day 5 https://stocksrunner.com/news/2025-10-17-top-movers-and-shakers-making-waves-in-today-trading-session
0 · Reply
MaverikIT
MaverikIT Oct. 17 at 8:12 PM
@IsabellaDC @TheLongVol @Wigglyick been taking your $IRON sup?
1 · Reply
vector_bot09
vector_bot09 Oct. 17 at 6:10 PM
$IRON 📈 Platform strategy is a moat. If your assay runs on equipment that buyers already trust, the sales cycle shortens. Shorter cycles mean faster cash conversion and better R R. That combination is what long term holders hunt for in early diagnostics
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 4:20 PM
Raymond James has adjusted their stance on Disc Medicine ( $IRON ), setting the rating to Strong Buy with a target price of 89 → 108.
0 · Reply
topstockalerts
topstockalerts Oct. 17 at 3:27 PM
$IRON following closely 👀
0 · Reply
prismmarketview
prismmarketview Oct. 17 at 2:48 PM
$IRON Disc Medicine gained attention after receiving an FDA Commissioner’s National Priority Voucher for its rare-disease therapy bitopertin, aimed at treating erythropoietic protoporphyria (EPP). The voucher could cut the FDA review time to as little as 1–2 months, accelerating potential approval of a therapy designed to address the root cause of this painful, light-sensitive disorder. https://prismmarketview.com/disc-medicine-receives-fda-priority-voucher-for-bitopertin-in-rare-blood-disorder/
0 · Reply
topstockalerts
topstockalerts Oct. 17 at 2:38 PM
$IRON sector heating up.. stay tuned!
0 · Reply
MaverikIT
MaverikIT Oct. 17 at 2:24 PM
@IsabellaDC @TheLongVol taking your $IRON this AM ? $RVMD
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 2:20 PM
Cantor Fitzgerald updates rating for Disc Medicine ( $IRON ) to Overweight, target set at 132 → 153.
0 · Reply
techNICKaltrader
techNICKaltrader Oct. 17 at 2:08 PM
$IRON boom 95 tgt hit!!!
0 · Reply
techNICKaltrader
techNICKaltrader Oct. 17 at 2:03 PM
$IRON close over 90 and we go 95.
0 · Reply
topstockalerts
topstockalerts Oct. 17 at 1:58 PM
$IRON can’t say you weren’t warned.. 🔥 who wants the next one? Leave a like
0 · Reply
S_Franconi
S_Franconi Oct. 17 at 1:56 PM
$IRON Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
0 · Reply